Source: http://www.google.com/patents/US7364724?dq=6,232,546
Timestamp: 2013-12-18 15:46:28
Document Index: 709913952

Matched Legal Cases: ['Application No. 2003248419', 'Application No. 2003248419', 'Application No. 2003248419', 'Application No. 02702211', 'Application No. 279', 'Application No. 200601204', 'Application No. 92', 'Application No. 92']

Patent US7364724 - Recombinant super-compound interferon - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsThis invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and therefore is useful to prevent and treat viral diseases and cancers. This invention also provides...http://www.google.com/patents/US7364724?utm_source=gb-gplus-sharePatent US7364724 - Recombinant super-compound interferonAdvanced Patent SearchPublication numberUS7364724 B2Publication typeGrantApplication numberUS 10/650,365Publication dateApr 29, 2008Filing dateAug 28, 2003Priority dateFeb 28, 2001Fee statusPaidAlso published asCA2439503A1, CN1245215C, CN1311035A, DE60234085D1, EP1371373A1, EP1371373A4, EP1371373B1, US8114395, US8425896, US20040202641, US20080305080, US20110189128, WO2002080958A1Publication number10650365, 650365, US 7364724 B2, US 7364724B2, US-B2-7364724, US7364724 B2, US7364724B2InventorsGuangwen Wei, Rongbing Guo, Renhuai ZhangOriginal AssigneeSichuan Biotechnology Research CenterExport CitationBiBTeX, EndNote, RefManPatent Citations (22), Non-Patent Citations (47), Referenced by (7), Classifications (24), Legal Events (2) External Links: USPTO, USPTO Assignment, EspacenetRecombinant super-compound interferonUS 7364724 B2Abstract This invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and therefore is useful to prevent and treat viral diseases and cancers. This invention also provides an artificial gene which codes for the super-compound interferon or its equivalent. Finally, this invention provides methods to produce recombinant super-compound interferon or its equivalent and various uses of said interferon.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4672108Jul 3, 1985Jun 9, 1987Hoffmann-La Roche Inc.Crystalline human leukocyte interferonUS4681930Aug 10, 1984Jul 21, 1987Hoffmann-La Roche Inc.Immune interferon and a method for its extraction and purificationUS4695623Dec 12, 1983Sep 22, 1987AmgenConsensus human leukocyte interferonUS4897471Sep 21, 1987Jan 30, 1990AmgenConsensus human leukocyte interferonUS5602232Dec 14, 1994Feb 11, 1997Schering CorporationMethod for producing metal-interferon-α crystalsUS5874304Jan 18, 1996Feb 23, 1999University Of Florida Research Foundation, Inc.Humanized green fluorescent protein genes and methodsUS5972331Dec 22, 1995Oct 26, 1999Schering CorporationCrystalline interferon alpha for pulmonary delivery and method for producing the sameUS6087478Jan 23, 1998Jul 11, 2000The Rockefeller UniversityCrystal of the N-terminal domain of a STAT protein and methods of use thereofUS6114145 *Dec 2, 1998Sep 5, 2000Human Genome Sciences, Inc.Synferon, a synthetic interferonUS6532437Oct 23, 1996Mar 11, 2003Cornell Research Foundation, Inc.Crystalline frap complexUS6546074Mar 27, 2001Apr 8, 2003Astex Technology LimitedProtein crystal structure and method for identifying protein modulatorsUS6579695Oct 11, 1996Jun 17, 2003President And Fellows Of Harvard CollegePhosphopantetheinyl transferases and uses thereofAU2003248419A1 Title not availableCN1375502AOct 25, 2001Oct 23, 2002南京药科大学Polyglycol modified recombinant human interferonCN1478545AJul 18, 2003Mar 3, 2004中国科学院微生物研究所Use of compound interferon in the treating of SARS diseaseEP0083734B1Dec 3, 1982Mar 5, 1986F. HOFFMANN-LA ROCHE &amp; CO. AktiengesellschaftCrystalline human leukocyte interferonEP0422697A1 *Dec 14, 1990Apr 17, 1991Amgen Inc.A consensus leukocyte interferon and a gene encoding itEP0736303B1Mar 30, 1996Aug 25, 1999F. Hoffmann-La Roche AgInterferon solutionEP0777495B1Oct 10, 1995Jul 19, 2000Schering CorporationStable, aqueous alfa interferon solution formulationsWO2005021777A2Aug 26, 2004Mar 10, 2005Huiyangtech Usa IncUses of spatial configuration to modulate protein functionWO2005034853A2Aug 26, 2004Apr 21, 2005Huiyangtech Usa IncUses of interferons with altered spatial structureWO2006134497A2Mar 9, 2006Dec 21, 2006Guangwen WeiUses of recombinant super-compound interferons* Cited by examinerNon-Patent CitationsReference1Advisory Action Before the Filing of and Appeal Brief for Guangwen WEI, U.S. Appl. No. 10/928,474, Filed Aug. 26, 2004, Dated May 22, 2007.2Apeler H, et al. "Expression of natural and synthetic genes encoding herpes simplex virus 1 protease in Escherichia coli and purification of the protein", European Journal Of Biochemistry / Febs. Aug. 1, 1997, vol. 247, No. 3, Aug. 1 1997, pp. 890-895, XP002318941, ISSN: 0014-2956.3Australian Examiner's Report for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Dec. 12, 2005.4Australian Examiner's Report for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Jun. 1, 2006.5Australian Notice of Acceptance for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Dec. 18, 2006.6Ausubel et al., Eds., 1999, Chapter Ten, "Analysis of Proteins," form Short Protocols in Molecular Biology, 4th ed., pp. 10-1 to 10-8.7Cinatl et al., 2003, "Treatment of SARS with Human Interferons," The Lancet, 362:293-294.8 *Day et al. Engineered Disulfide Bond Greatly Increases Specific Activity of RecombinNT Murine Interferon-beta (1992), J. of Interferon Res. 12, pp. 139-143.9Day et al., 1992, "Engineered disulfide bond greatly increases specific activity of recombinant murine interferon-beta," Journal of Interferon Res., 12: 139-143.10Duan et al., 2003, "Anti-SARS virus activities of different recombinant human interferons in cell culture system," Chinese J. Clin. Virol., 17(3):205-208.11EPO Supplementary European Search Report, Application No. EP 02702211, Filed Feb. 28, 2002, Date of completion of the search: Feb. 23, 2005.12European Communication for Sichuan Biotechnology Research Center, European Application No. 02702211.D, Filed Sep. 25, 2003, Dated Dec. 14, 2006.13Guzman Luz-Maria, et al. "Tight regulation, modulation, and high-level expression by vectors containing the arabinose P-BAD promoter", Journal of Bacteriology, vol. 177, No. 14, 1995, pp. 4121-4130, XP002121022, ISSN: 0021-9193.14Higgins et al., 1983, "Intranasal Interferon as Protection Against Experimental Respiratory Coronavirus Infection in Volunteers," Antimicrobial Agents and Chemotherapy, 24(5):713-715.15Holland, C.C. and T.L. Wright, 1994, "New approaches to treatment of chronic viral hepatitis," Pathology (Phila.), 3(1).16Huang Wanzhi, et al. "Use of the arabinose pbad promoter for tightly regulated display of proteins on bacteriophage", Gene (Amsterdam), vol. 251, No. 2, Jun. 27, 2000, pp. 187-197, XP004206676, ISSN: 0378-1119.17Indian Examination Report for Sichuan Biotechnology Research Center, Indian Application No. 279/MUM/2004, Filed Mar. 5, 2004, Dated Aug. 2, 2007.18International Preliminary Examination Report, Application No. PCT/CN02/00128 for Sichuan Biotechnology Research Center, "Recombination Super Compound Interferon Used as Helatitis B Surface Antigen and E Antigen Inhibitor," Filed Feb. 28, 2002, Dated Feb. 15, 2004.19International Publication No. WO 83/04053 for Amgen Inc et al., Published Nov. 24, 1983. PCT/US83/00605 "The Manufacture and Expression of Large Structural Genes".20International Publication No. WO 93/21229 for Amgen Inc et al., Published Oct. 28, 1993. PCT/US93/04471 "Methods and Compositions for the Treatment of Diseases with Interferon While Reducing Side Effects".21International Publication No. WO/02/80958 for Guangwen Wei, Published Oct. 17, 2002. PCT/CN02/00128 "Recombination Super Compound Interferon Used as Hepatitis B Surface Antigen and E Antigen Inhibitor".22International Search Report for International Application No. PCT/US04/28068, filed Aug. 26, 2004 for Huiyangtech (USA) Inc., dated Mar. 4, 2005.23International Search Report, Application No. PCT/CN02/00128 for Sichuan Biotechnology Research Center, "Recombination Super Compound interferon Used as Hepatitis B Surface Antigen and E Antigen Inhibito," Filed Feb. 28, 2002, Dated Aug. 8, 2002, Date of Completion of the Search: Jul. 23, 2002.24International Search Report, Application No. PCT/US2004/028067 for Huiyangtech, Inc., "Uses of interferons with altered spatial structure,"Filed Aug. 26, 2004, Dated Feb. 27, 2006, Date of Completion of the Search: Nov. 2, 2005.25Ivan Amato, Jan. 22, 2007, "Silent No Longer: Researchers Unearth Another Stratum of Meaning in the Genetic Code," Chemical and Engineering News, 85(4):38-40.26Malaysian Examiner's Report for Sichuan Biotechnology Research Center, Malaysian Application No. PI 20033246, Filed Aug. 28, 2003, Dated Mar. 8, 2007.27Nackley, A.G. et al., Dec. 22, 2006, "Human Catechol-O-Methyltransferase Haplotypes Modulate Protein Expression by Altering mRNA Secondary Structure," Science, 314:1930-1932.28Nasoff et al., 1999, "High-level expression of human genes in E. coli," Expression, 6(2): 10-11.29 *Nasoff, M. High-Level Expression of Human Genes in E. coli. (1999), Expression vol. 6, No. 2, pp. 10-11.30Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority (International Search Report and Written Opinion included), Application No. PCT/IB2006/002340, Filed Mar. 9, 2006, Dated May 10, 2007.31PCT Notification of Transmittal of International Preliminary Report on Patentability for Huiyangtech (USA) Inc., Int'l Application No. PCT/US04/28068, Filed Aug. 26, 2004, Dated May 13, 2005.32Pyrc, K, et al., 2007, "Antiviral strategies against human coronaviruses," Infectious Disorders - Drug Targets, 7:59-66.33Singapore Written Opinion for Huiyangtech (USA), Inc., Singapore Application No. 200601204-1, Filed Feb. 23, 2006, Dated Jul. 19, 2007.34Taiwanese Formal Rejection for Sichuan Biotechnology Research Center, Taiwanese Application No. 92,123,846, Filed Aug. 28, 2003, Dated Dec. 29, 2006.35Taiwanese Office Action for Sichuan Biotechnology Research Center, Taiwanese Application No. 92,123,846, Filed Aug. 28, 2003, Dated Sep. 21, 2006.36U.S. Office Action for Guangwen WEI, U.S. Appl. No. 10/927,975, Filed Aug. 26, 2004, Dated Apr. 3, 2007.37U.S. Office Action for Guangwen WEI, U.S. Appl. No. 10/927,975, Filed Aug. 26, 2004, Dated Sep. 19, 2007.38U.S. Office Action for Guangwen WEI, U.S. Appl. No. 10/928,474, Filed Aug. 26, 2004, Dated Aug. 22, 2006.39U.S. Office Action for Guangwen WEI, U.S. Appl. No. 10/928,474, Filed Aug. 26, 2004, Dated Aug. 9, 2007.40U.S. Office Action for Guangwen WEI, U.S. Appl. No. 10/928,474, Filed Aug. 26, 2004, Dated Feb. 9, 2007.41U.S. Office Action for Guangwen WEI, U.S. Appl. No. 10/928,956, Filed Aug. 26, 2004, Dated Dec. 15, 2006.42U.S. Office Action for Guangwen WEI, U.S. Appl. No. 10/928.956, Filed Aug. 26, 2004, Dated Jun. 14, 2007.43U.S. Office Action for Guangwen WEI, U.S. Appl. No. 11/077,813, Filed Mar. 10, 2005, Dated Aug. 1, 2007.44U.S. Office Action for Guangwen WEI, U.S. Appl. No. 11/077,813, Filed Mar. 10, 2005, Dated Aug. 8, 2006.45U.S. Office Action for Guangwen WEI, U.S. Appl. No. 11/077,813, Filed Mar. 10, 2005, Dated Nov. 27, 2006.46Written Opinion of the International Searching Authority for International Application No. PCT/US04/28068, filed Aug. 26, 2004 for Huiyangtech (USA) Inc., dated Mar. 4, 2004.47Zhao, Z. et al., 2003, "Description and Clinical treatment of an early outbreak of severe Acute Respiratory Syndrome (SARS) in Guangzhou, PR China," Journal of Med. Microbiol., 52:715-720.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS7585647Aug 26, 2004Sep 8, 2009Guangwen WeiNucleic acid encoding recombinant interferonUS8114395Apr 18, 2008Feb 14, 2012Sichuan Biotechnology Research CenterTreatment of viral diseases with recombinant interferon αUS8287852Sep 4, 2009Oct 16, 2012Superlab Far East LimitedTreatment of viral diseases with recombinant interferon αUS8415151Dec 17, 2010Apr 9, 2013Guangwen WeiCrystalline recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereofUS8425896Feb 1, 2011Apr 23, 2013Sichuan Biotechnology Research CenterTreatment of tumors with recombinant interferon alphaEP2514761A1 *Dec 16, 2010Oct 24, 2012Sichuan Huiyang Life Science & Technology Corp.Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereofWO2011072487A1Dec 16, 2010Jun 23, 2011Sichuan Huiyang Life Science & Technology Corp.Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof* Cited by examinerClassifications U.S. Classification424/85.7, 435/71.1, 536/23.52, 435/252.3, 435/69.52International ClassificationA61P35/02, C07H21/04, A61P31/20, C12N15/20, A61P31/22, A61K38/00, A61P1/16, A61P31/16, A61P31/18, C07K14/555, A61P31/12, C12P21/04, C12N15/09, C12N1/20, A61K38/21, A61P31/14Cooperative ClassificationC07K14/555, A61K38/00European ClassificationC07K14/555Legal EventsDateCodeEventDescriptionSep 14, 2011FPAYFee paymentYear of fee payment: 4Jun 15, 2004ASAssignmentOwner name: SICHUAN BIOTECHNOLOGY RESEARCH CENTER, CHINAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WEI, GUANGWEN;GUO, RONGBING;ZHANG, RENHUAI;REEL/FRAME:015471/0411Effective date: 20030929RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google